Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies
The CRISPR Journal · 2023
DOI: 10.1089/crispr.2022.0086 ↗Kurz gefasst
Fachartikel in der Zeitschrift The CRISPR Journal, 2023. Verfasst von Guillermo Ureña-Bailén und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Pediatrics, Oncology and Hematology, University Children's Hospital, Tübingen, Germany. Hauptthemen laut MEDLINE: Hemoglobinopathies, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Cellular therapies hold enormous potential for the cure of severe hematological and oncological disorders. The forefront of innovative gene therapy approaches including therapeutic gene editing and hematopoietic stem cell transplantation needs to be processed by good manufacturing practice to ensure safe application in patients. In the present study, an effective transfection protocol for automated clinical-scale production of genetically modified hematopoietic stem and progenitor cells (HSPCs) using the CliniMACS Prodigy® system including the CliniMACS Electroporator (Miltenyi Biotec) was established. As a proof-of-concept, the enhancer of the BCL11A gene, clustered regularly interspaced short palindromic repeat (CRISPR) target in ongoing clinical trials for β-thalassemia and sickle-cell disease treatment, was disrupted by the CRISPR-Cas9 system simulating a large-scale clinical scenario, yielding 100 million HSPCs with high editing efficiency. In vitro erythroid differentiation and high-performance liquid chromatography analyses corroborated fetal hemoglobin resurgence in edited samples, supporting the feasibility of running the complete process of HSPC gene editing in an automated closed system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of General Pediatrics, Oncology and Hematology, University Children's Hospital, Tübingen, Germany.
- Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
- Institute for Clinical Chemistry and Laboratory Medicine, University Hospital, Freiburg, Germany.
- Abu Dhabi Stem Cells Center, Abu Dhabi, United Arab Emirates.
ORCID-Profile: Guillermo Ureña-Bailén, Stefan Wild, Markus Mezger
Zitieren
APA
Ureña-Bailén, G., Block, M., Grandi, T., Aivazidou, F., Quednau, J., Krenz, D., Daniel-Moreno, A., Lamsfus-Calle, A., Epting, T., Handgretinger, R., Wild, S., & Mezger, M. (2023). Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies. The CRISPR Journal. https://doi.org/10.1089/crispr.2022.0086
Vancouver
Ureña-Bailén G, Block M, Grandi T, Aivazidou F, Quednau J, Krenz D, et al. Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies. The CRISPR Journal. 2023. doi:10.1089/crispr.2022.0086
BibTeX
@article{UreaBailn2023,
author = {Ureña-Bailén, Guillermo and Block, Milena and Grandi, Tommaso and Aivazidou, Faidra and Quednau, Jona and Krenz, Dariusz and Daniel-Moreno, Alberto and Lamsfus-Calle, Andrés and Epting, Thomas and Handgretinger, Rupert and Wild, Stefan and Mezger, Markus},
title = {Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies},
journal = {The CRISPR Journal},
year = {2023},
doi = {10.1089/crispr.2022.0086}
}
EUVIMED